<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81892</article-id><article-id pub-id-type="doi">10.7554/eLife.81892</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-286872"><name><surname>Lee</surname><given-names>Dongwon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-58077"><name><surname>Chen</surname><given-names>Wu</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7400-0519</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286873"><name><surname>Kaku</surname><given-names>Heet Naresh</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286874"><name><surname>Zhuo</surname><given-names>Xinming</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-255630"><name><surname>Chao</surname><given-names>Eugene S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286875"><name><surname>Soriano</surname><given-names>Armand</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-286876"><name><surname>Kuncheria</surname><given-names>Allen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286877"><name><surname>Flores</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-143692"><name><surname>Kim</surname><given-names>Joo Hyun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293691"><name><surname>Rivera</surname><given-names>Armando</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7076-8566</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231701"><name><surname>Rigo</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-286878"><name><surname>Jafar-nejad</surname><given-names>Paymaan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-286879"><name><surname>Beaudet</surname><given-names>Arthur L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-286880"><name><surname>Caudill</surname><given-names>Matthew S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-255327"><name><surname>Xue</surname><given-names>Mingshan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1463-8884</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf6"/></contrib><aff id="aff1"><institution content-type="dept">Department of Neuroscience</institution>, <institution>Baylor College of Medicine</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Molecular and Human Genetics</institution>, <institution>Baylor College of Medicine</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution>Ionis Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Carlsbad</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-224822"><name><surname>Pleasure</surname><given-names>Samuel</given-names></name><role>Reviewing editor</role><aff><institution>University of California, San Francisco</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>wu.chen@bcm.edu</email> (WC);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>mxue@bcm.edu</email> (MX);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>03</day><month>01</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e81892</elocation-id><history><date date-type="received"><day>15</day><month>07</month><year>2022</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Lee et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Lee et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81892-v1.pdf"/><abstract><p><italic>UBE3A</italic> encodes ubiquitin protein ligase E3A, and in neurons its expression from the paternal allele is repressed by the <italic>UBE3A</italic> antisense transcript (<italic>UBE3A-ATS</italic>). This leaves neurons susceptible to loss-of-function of maternal <italic>UBE3A</italic>. Indeed, Angelman syndrome, a severe neurodevelopmental disorder, is caused by maternal <italic>UBE3A</italic> deficiency. A promising therapeutic approach to treating Angelman syndrome is to reactivate the intact paternal <italic>UBE3A</italic> by suppressing <italic>UBE3A-ATS</italic>. Prior studies show that many neurological phenotypes of maternal <italic>Ube3a</italic> knockout mice can only be rescued by reinstating <italic>Ube3a</italic> expression in early development, indicating a restricted therapeutic window for Angelman syndrome. Here we report that reducing <italic>Ube3a-ATS</italic> by antisense oligonucleotides in juvenile or adult maternal <italic>Ube3a</italic> knockout mice rescues the abnormal electroencephalogram rhythms and sleep disturbance, two prominent clinical features of Angelman syndrome. Importantly, the degree of phenotypic improvement correlates with the increase of Ube3a protein levels. These results indicate that the therapeutic window of genetic therapies for Angelman syndrome is broader than previously thought, and electroencephalogram power spectrum and sleep architecture should be used to evaluate the clinical efficacy of therapies.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007137</institution-id><institution>Texas Children's Hospital</institution></institution-wrap></funding-source><award-id>Main Street America Fund</award-id><principal-award-recipient><name><surname>Xue</surname><given-names>Mingshan</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R01NS100893</award-id><principal-award-recipient><name><surname>Xue</surname><given-names>Mingshan</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>R01MH117089</award-id><principal-award-recipient><name><surname>Xue</surname><given-names>Mingshan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Armand Soriano, is a paid employee of Ionis Pharmaceuticals..</p></fn><fn fn-type="conflict" id="conf3"><p>Frank Rigo, is a paid employee of Ionis Pharmaceuticals..</p></fn><fn fn-type="conflict" id="conf4"><p>Paymaan Jafar-nejad, is a paid employee of Ionis Pharmaceuticals..</p></fn><fn fn-type="conflict" id="conf5"><p>Arthur L Beaudet, is a paid employee of Luna Genetics..</p></fn><fn fn-type="conflict" id="conf6"><p>Mingshan Xue, MX is a consultant to Capsida Biotherapeutics and receives funds from Capsida Biotherapeutics for research not related to this study..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AN-6544) of Baylor College of Medicine.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figure 3, Figure 3-supplement 1, Figure 3-supplement 3, and Figure 3-supplement 4.</p></sec><supplementary-material><ext-link xlink:href="elife-81892-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>